Addition of the Gamma-Secretase Inhibitor RO4929097 (IND 105,994) to Erlotinib in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)

Trial Profile

Addition of the Gamma-Secretase Inhibitor RO4929097 (IND 105,994) to Erlotinib in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)

Discontinued
Phase of Trial: Phase I/II

Latest Information Update: 01 Oct 2015

At a glance

  • Drugs Erlotinib (Primary) ; RG 4733 (Primary)
  • Indications Non-small cell lung cancer
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 28 Sep 2015 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
    • 16 Oct 2012 Planned end date changed from 1 Jul 2011 to 1 Dec 2015 as reported by ClinicalTrials.gov.
    • 20 Jul 2012 Status changed from recruiting to active, no longer recruiting as reported by M.D. Anderson Cancer Center.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top